Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence

✍ Scribed by David J. van Westerloo; Erik A. Rauws; Daan Hommes; Alex F. de Vos; Tom van der Poll; Barbara L. Powers; Paul Fockens; Marcel G.W. Dijkgraaf; Marco J. Bruno

• Book ID: 119245436
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 225 KB
• Volume: 68
• Category: Article
• ISSN: 1097-6779
• DOI: 10.1016/j.gie.2008.01.034